Agios Pharmaceuticals Employees 2024

Agios Pharmaceuticals Aktienanalyse

What does Agios Pharmaceuticals do?

Agios Pharmaceuticals Inc. is a US biopharmaceutical company specializing in the development of treatment options for rare genetic disorders and cancer. The company was founded in 2008 by David Schenkein, Lewis Cantley, and Tak Mak and is headquartered in Cambridge, Massachusetts. The history of Agios Pharmaceuticals Inc. began with the discovery of IDH1 mutations, which are frequently found in many types of cancer. The founders of Agios recognized the significance of this discovery and laid the foundation for the development of drugs targeting this mutation. Agios' business model is to develop innovative therapeutics for diseases that are often neglected by other companies. The company focuses on researching enzymes that play important roles in genetic disorders and cancer processes. Agios collaborates closely with other companies and research institutions to quickly translate its research findings into clinical research and subsequent patient treatment. Additionally, the company has established itself as a pioneer in the application of artificial intelligence in drug development in recent years. Agios divides its portfolio into two main areas: oncology and rare genetic disorders. In oncology, the company utilizes targeted therapies based on a deep understanding of the underlying cancer biology. Therapeutic approaches include enzyme inhibitors, immunotherapies, and cell therapies. Agios has several promising candidates in clinical development in this area, including Idhifa for the treatment of acute myeloid leukemia, as well as Ivosidenib and Ag-120, both used to treat brain tumors. In the field of rare genetic disorders, Agios specializes in a group of enzyme defects known as citric acid cycle disorders. Agios is the only provider of drugs targeting these enzymes. The company recently received approval for Tibsovo for the treatment of acute myeloid leukemia in the United States. Agios aims to continuously expand its pipeline of therapeutics to meet the unmet need for treatments for rare diseases and cancer. The company has an extensive research pipeline, with several drugs in preclinical and clinical development. Agios works closely with other companies and research institutions to quickly translate its research findings into clinical development and subsequent patient treatment. Overall, Agios Pharmaceuticals has made impressive strides in recent years and has established itself as a key player in the biopharmaceutical industry. The company specializes in developing innovative therapies for rare genetic disorders and cancer and collaborates closely with other companies and research institutions. With its extensive research pipeline and the application of artificial intelligence, Agios is well-positioned to contribute to the development of new therapeutic options in the future. Agios Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Agios Pharmaceuticals's Employee Base

Agios Pharmaceuticals's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Agios Pharmaceuticals's operational capacity and future potential.

Year-to-Year Comparison

Assessing Agios Pharmaceuticals's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Agios Pharmaceuticals's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Agios Pharmaceuticals’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Agios Pharmaceuticals Stock

How many employees does Agios Pharmaceuticals have this year?

Agios Pharmaceuticals has 562 undefined employees this year.

How many employees did Agios Pharmaceuticals have compared to the previous year?

Compared to the previous year, Agios Pharmaceuticals had 0% more employees.

What impact did the number of employees have on the company Agios Pharmaceuticals?

The number of employees has a direct impact on the efficiency and productivity of Agios Pharmaceuticals. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Agios Pharmaceuticals?

The number of employees can also have an impact on investors of Agios Pharmaceuticals, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Agios Pharmaceuticals affect the company?

An increase in equity of Agios Pharmaceuticals can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Agios Pharmaceuticals's equity affect the company?

A reduction in equity of Agios Pharmaceuticals can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Agios Pharmaceuticals?

Some factors that can influence the equity of Agios Pharmaceuticals include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Agios Pharmaceuticals so important for investors?

The equity of Agios Pharmaceuticals is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Agios Pharmaceuticals influence the company?

The number of employees at Agios Pharmaceuticals can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Agios Pharmaceuticals evolved in recent years?

In recent years, the number of employees at Agios Pharmaceuticals has changed by 0.

How many employees does Agios Pharmaceuticals currently have?

Agios Pharmaceuticals currently has 562 undefined employees.

Why is the number of employees important for investors of Agios Pharmaceuticals?

The number of employees is important for investors of Agios Pharmaceuticals as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Agios Pharmaceuticals take to change the number of employees?

To change the number of employees, Agios Pharmaceuticals can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Agios Pharmaceuticals pay?

Over the past 12 months, Agios Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agios Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Agios Pharmaceuticals?

The current dividend yield of Agios Pharmaceuticals is .

When does Agios Pharmaceuticals pay dividends?

Agios Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agios Pharmaceuticals?

Agios Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Agios Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agios Pharmaceuticals located?

Agios Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agios Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agios Pharmaceuticals from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Agios Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Agios Pharmaceuticals in the year 2023?

In the year 2023, Agios Pharmaceuticals distributed 0 USD as dividends.

In which currency does Agios Pharmaceuticals pay out the dividend?

The dividends of Agios Pharmaceuticals are distributed in USD.